On November 25, Dr. Zhao Lijun, R&D Deputy Director at BioGrowing, was invited to attend the roundtable session of The 7th Nutrition and Health Industry Entrepreneurs Conference. Centered on the theme “Efficacy Evaluation of Akkermansia muciniphila Strains for Weight Control,” she provided an in-depth explanation of the mechanisms of action, application potential, and key challenges in the standardization of efficacy assessment for Akkermansia muciniphila in weight management. Her insights fully reflected BioGrowing’s solid scientific foundation and forward-looking industrial strategy in probiotics innovation.
The Akkermansia muciniphila WST01 live strain is the first live Akkermansia strain in China validated through a randomized, controlled clinical trial, with related findings published in the top-tier journal Cell Metabolism. It has demonstrated significant efficacy in body-weight control and metabolic improvement among individuals with type 2 diabetes. Meanwhile, AKKBG-001™ strain is produced through proprietary anaerobic fermentation and a high-fidelity inactivation process, with each capsule standardized to contain 30 billion TFU. The strain offers multiple health benefits, including weight management, energy metabolism enhancement, and gut barrier repair.
Having achieved mass production of both strains, BioGrowing has demonstrated its comprehensive technology pathway—from cutting-edge research to industrial implementation. This not only solidifies the company's leadership in next-generation probiotics but also provides the industry with innovative solutions validated by clinical evidence and proven industrial prowess.
